EcoDrugPlus

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSPKIG00000008817
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSPKIG00000004803
Gene Symbol: HTR3A
3 Cross references
132 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSPKIG00000008861
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSPKIG00000019566
Gene Symbol: HTR4
3 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSPKIG00000012962
Gene Symbol: HTR5A
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSPKIG00000020904
Gene Symbol: HTR5A
1 Cross references
207 Possible Orthologues:

60s Ribosomal Protein L10-Like

Ensembl ID : ENSPKIG00000024440
Gene Symbol: LOC111842267
3 Cross references
409 Possible Orthologues:

60s Ribosomal Protein L18a

Ensembl ID : ENSPKIG00000002081
Gene Symbol: LOC111847002
3 Cross references
368 Possible Orthologues:

60s Ribosomal Protein L18a-Like

Ensembl ID : ENSPKIG00000018947
Gene Symbol: LOC111845655
3 Cross references
368 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSPKIG00000009673
Gene Symbol: LOC111837806
3 Cross references
376 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSPKIG00000021559
Gene Symbol: LOC111855903
3 Cross references
376 Possible Orthologues:

60s Ribosomal Protein L24-Like

Ensembl ID : ENSPKIG00000005608
Gene Symbol: LOC111841881
3 Cross references
264 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).